Tuberculosis Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Active TB, Latent TB), By Therapy, By Route Of Administration, By Dosage Form, By Distribution Channel, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global tuberculosis therapeutics market size was exhibited at USD 2.04 billion in 2022 and is projected to hit around USD 3.36 billion by 2032, growing at a CAGR of 5.11% during the forecast period 2023 to 2032.

Key Pointers:

• Active TB segment dominated et in 2022 and is attributable to the increasing prevalence and recurrence of condition
• Second line therapy segment is expected to show fastest growth rate over the forecast period owing to increasing demand and the rising research and development for development of newer second-line therapy drugs
• Oral segment dominated the market in 2022 attributable to the availability of a large number of drugs in form of tablets.
• The COVID-19 pandemic influenced the market adversely attributable to the reduced funding for therapeutics and decline in diagnosis rate of disease.
• MEA held the largest market share in 2022 which can be attributed to the enhanced focus on early diagnosis of the disease and improvement in adoption rate of treatments.

 Tuberculosis Therapeutics Market Report Scope

The growth is due to factors such as the rising prevalence of tuberculosis, increasing investments in healthcare infrastructure, and the increasing geriatric population. Tuberculosis was the 13th leading cause of death worldwide with an estimated prevalence of 15.9 million in 2022.

A significant shift in TB care has been brought about by the COVID-19 pandemic. Patients with TB that were identified during the COVID-19 pandemic displayed more extensive pulmonary manifestations. Increased household transmission brought on by precautions taken to curb the spread of COVID-19 infection may be the cause of growth in latent TB infection and active TB in children of patient families. These limitations put in place by governments have altered how patient care is provided, having a detrimental effect on the health of the patients by delaying the treatment of acute emergencies, exacerbating chronic diseases, and causing psychological distress.

With the increasing cases of TB, testing has also been on a rise, further leading to the launch of newer testing kits into the market. Recently, in December 2022, a genetic test for determining TB has been launched by a collaboration between LifeCell and HaystackAnalytics. This launch aims to tackle the spread of tuberculosis by providing an affordable, accurate, and timely diagnosis of drug resistance. A significant rise in drug-resistant infection is being witnessed, which requires appropriate diagnosis so that a precise therapeutics regime can be provided.

Moreover, the market has been witnessing significant growth owing to the increasing prevalence of multidrug-resistant (MDR) tuberculosis. According to the WHO, the estimated cases of MDR/RR-TB were around 3.6% globally in 2021. With increasing incidence rates, several steps and initiatives are being taken to tackle the alarming condition of tuberculosis. For instance, in October 2022, a transformative alliance was formed, which will aid the World Health Organization's strategy to end the global tuberculosis epidemic by 2035.

However, the market growth is being restrained by the high costs associated with the treatment of the condition. MDR TB is one of the major public health concerns globally. Half a million cases of MDR TB1 are estimated to occur globally each year, which include extensive drug-resistant cases. Although the cases are increasing rapidly, the treatment is very expensive, takes a longer time to complete, and has potentially life-threatening side effects. According to the CDC, the average direct treatment cost associated with tuberculosis is around USD 182,186 in the case of MDR TB.

Some of the prominent players in the Tuberculosis Therapeutics Market include:

• AstraZeneca
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Viatris Inc. (Mylan N.V.)
• Teva Pharmaceutical Industries, Ltd.
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Tuberculosis Therapeutics market.

By Disease Type 

• Active TB
• Latent TB

By Therapy 

• First-Line Therapy
• Second-Line Therapy

By Route of Administration 

• Oral
• Parenteral
• Others

By Dosage Form 

• Tablets
• Capsules
• Injection
• Others

By Distribution Channel 

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)